Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro

Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often infiltrated by malignant cells, to cancer progression is largely unknown. Thus, this study aimed to determine if periprostatic adipose tissue is linked with aggre...

Full description

Saved in:
Bibliographic Details
Published inJournal of experimental & clinical cancer research Vol. 31; no. 1; p. 32
Main Authors Ribeiro, Ricardo, Monteiro, Cátia, Cunha, Virgínia, Oliveira, Maria José, Freitas, Mariana, Fraga, Avelino, Príncipe, Paulo, Lobato, Carlos, Lobo, Francisco, Morais, António, Silva, Vítor, Sanches-Magalhães, José, Oliveira, Jorge, Pina, Francisco, Mota-Pinto, Anabela, Lopes, Carlos, Medeiros, Rui
Format Journal Article
LanguageEnglish
Published England BioMed Central 02.04.2012
BioMed Central Ltd
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often infiltrated by malignant cells, to cancer progression is largely unknown. Thus, this study aimed to determine if periprostatic adipose tissue is linked with aggressive tumor biology in prostate cancer. Supernatants of whole adipose tissue (explants) or stromal vascular fraction (SVF) from paired fat samples of periprostatic (PP) and pre-peritoneal visceral (VIS) anatomic origin from different donors were prepared and analyzed for matrix metalloproteinases (MMPs) 2 and 9 activity. The effects of those conditioned media (CM) on growth and migration of hormone-refractory (PC-3) and hormone-sensitive (LNCaP) prostate cancer cells were measured. We show here that PP adipose tissue of overweight men has higher MMP9 activity in comparison with normal subjects. The observed increased activities of both MMP2 and MMP9 in PP whole adipose tissue explants, likely reveal the contribution of adipocytes plus stromal-vascular fraction (SVF) as opposed to SVF alone. MMP2 activity was higher for PP when compared to VIS adipose tissue. When PC-3 cells were stimulated with CM from PP adipose tissue explants, increased proliferative and migratory capacities were observed, but not in the presence of SVF. Conversely, when LNCaP cells were stimulated with PP explants CM, we found enhanced motility despite the inhibition of proliferation, whereas CM derived from SVF increased both cell proliferation and motility. Explants culture and using adipose tissue of PP origin are most effective in promoting proliferation and migration of PC-3 cells, as respectively compared with SVF culture and using adipose tissue of VIS origin. In LNCaP cells, while explants CM cause increased migration compared to SVF, the use of PP adipose tissue to generate CM result in the increase of both cellular proliferation and migration. Our findings suggest that the PP depot has the potential to modulate extra-prostatic tumor cells' microenvironment through increased MMPs activity and to promote prostate cancer cell survival and migration. Adipocyte-derived factors likely have a relevant proliferative and motile role.
AbstractList Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often infiltrated by malignant cells, to cancer progression is largely unknown. Thus, this study aimed to determine if periprostatic adipose tissue is linked with aggressive tumor biology in prostate cancer. Supernatants of whole adipose tissue (explants) or stromal vascular fraction (SVF) from paired fat samples of periprostatic (PP) and pre-peritoneal visceral (VIS) anatomic origin from different donors were prepared and analyzed for matrix metalloproteinases (MMPs) 2 and 9 activity. The effects of those conditioned media (CM) on growth and migration of hormone-refractory (PC-3) and hormone-sensitive (LNCaP) prostate cancer cells were measured. We show here that PP adipose tissue of overweight men has higher MMP9 activity in comparison with normal subjects. The observed increased activities of both MMP2 and MMP9 in PP whole adipose tissue explants, likely reveal the contribution of adipocytes plus stromal-vascular fraction (SVF) as opposed to SVF alone. MMP2 activity was higher for PP when compared to VIS adipose tissue. When PC-3 cells were stimulated with CM from PP adipose tissue explants, increased proliferative and migratory capacities were observed, but not in the presence of SVF. Conversely, when LNCaP cells were stimulated with PP explants CM, we found enhanced motility despite the inhibition of proliferation, whereas CM derived from SVF increased both cell proliferation and motility. Explants culture and using adipose tissue of PP origin are most effective in promoting proliferation and migration of PC-3 cells, as respectively compared with SVF culture and using adipose tissue of VIS origin. In LNCaP cells, while explants CM cause increased migration compared to SVF, the use of PP adipose tissue to generate CM result in the increase of both cellular proliferation and migration. Our findings suggest that the PP depot has the potential to modulate extra-prostatic tumor cells' microenvironment through increased MMPs activity and to promote prostate cancer cell survival and migration. Adipocyte-derived factors likely have a relevant proliferative and motile role.
BACKGROUND: Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often infiltrated by malignant cells, to cancer progression is largely unknown. Thus, this study aimed to determine if periprostatic adipose tissue is linked with aggressive tumor biology in prostate cancer. METHODS: Supernatants of whole adipose tissue (explants) or stromal vascular fraction (SVF) from paired fat samples of periprostatic (PP) and pre-peritoneal visceral (VIS) anatomic origin from different donors were prepared and analyzed for matrix metalloproteinases (MMPs) 2 and 9 activity. The effects of those conditioned media (CM) on growth and migration of hormone-refractory (PC-3) and hormone-sensitive (LNCaP) prostate cancer cells were measured. RESULTS: We show here that PP adipose tissue of overweight men has higher MMP9 activity in comparison with normal subjects. The observed increased activities of both MMP2 and MMP9 in PP whole adipose tissue explants, likely reveal the contribution of adipocytes plus stromal-vascular fraction (SVF) as opposed to SVF alone. MMP2 activity was higher for PP when compared to VIS adipose tissue. When PC-3 cells were stimulated with CM from PP adipose tissue explants, increased proliferative and migratory capacities were observed, but not in the presence of SVF. Conversely, when LNCaP cells were stimulated with PP explants CM, we found enhanced motility despite the inhibition of proliferation, whereas CM derived from SVF increased both cell proliferation and motility. Explants culture and using adipose tissue of PP origin are most effective in promoting proliferation and migration of PC-3 cells, as respectively compared with SVF culture and using adipose tissue of VIS origin. In LNCaP cells, while explants CM cause increased migration compared to SVF, the use of PP adipose tissue to generate CM result in the increase of both cellular proliferation and migration. CONCLUSIONS: Our findings suggest that the PP depot has the potential to modulate extra-prostatic tumor cells' microenvironment through increased MMPs activity and to promote prostate cancer cell survival and migration. Adipocyte-derived factors likely have a relevant proliferative and motile role.
Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often infiltrated by malignant cells, to cancer progression is largely unknown. Thus, this study aimed to determine if periprostatic adipose tissue is linked with aggressive tumor biology in prostate cancer.BACKGROUNDObesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often infiltrated by malignant cells, to cancer progression is largely unknown. Thus, this study aimed to determine if periprostatic adipose tissue is linked with aggressive tumor biology in prostate cancer.Supernatants of whole adipose tissue (explants) or stromal vascular fraction (SVF) from paired fat samples of periprostatic (PP) and pre-peritoneal visceral (VIS) anatomic origin from different donors were prepared and analyzed for matrix metalloproteinases (MMPs) 2 and 9 activity. The effects of those conditioned media (CM) on growth and migration of hormone-refractory (PC-3) and hormone-sensitive (LNCaP) prostate cancer cells were measured.METHODSSupernatants of whole adipose tissue (explants) or stromal vascular fraction (SVF) from paired fat samples of periprostatic (PP) and pre-peritoneal visceral (VIS) anatomic origin from different donors were prepared and analyzed for matrix metalloproteinases (MMPs) 2 and 9 activity. The effects of those conditioned media (CM) on growth and migration of hormone-refractory (PC-3) and hormone-sensitive (LNCaP) prostate cancer cells were measured.We show here that PP adipose tissue of overweight men has higher MMP9 activity in comparison with normal subjects. The observed increased activities of both MMP2 and MMP9 in PP whole adipose tissue explants, likely reveal the contribution of adipocytes plus stromal-vascular fraction (SVF) as opposed to SVF alone. MMP2 activity was higher for PP when compared to VIS adipose tissue. When PC-3 cells were stimulated with CM from PP adipose tissue explants, increased proliferative and migratory capacities were observed, but not in the presence of SVF. Conversely, when LNCaP cells were stimulated with PP explants CM, we found enhanced motility despite the inhibition of proliferation, whereas CM derived from SVF increased both cell proliferation and motility. Explants culture and using adipose tissue of PP origin are most effective in promoting proliferation and migration of PC-3 cells, as respectively compared with SVF culture and using adipose tissue of VIS origin. In LNCaP cells, while explants CM cause increased migration compared to SVF, the use of PP adipose tissue to generate CM result in the increase of both cellular proliferation and migration.RESULTSWe show here that PP adipose tissue of overweight men has higher MMP9 activity in comparison with normal subjects. The observed increased activities of both MMP2 and MMP9 in PP whole adipose tissue explants, likely reveal the contribution of adipocytes plus stromal-vascular fraction (SVF) as opposed to SVF alone. MMP2 activity was higher for PP when compared to VIS adipose tissue. When PC-3 cells were stimulated with CM from PP adipose tissue explants, increased proliferative and migratory capacities were observed, but not in the presence of SVF. Conversely, when LNCaP cells were stimulated with PP explants CM, we found enhanced motility despite the inhibition of proliferation, whereas CM derived from SVF increased both cell proliferation and motility. Explants culture and using adipose tissue of PP origin are most effective in promoting proliferation and migration of PC-3 cells, as respectively compared with SVF culture and using adipose tissue of VIS origin. In LNCaP cells, while explants CM cause increased migration compared to SVF, the use of PP adipose tissue to generate CM result in the increase of both cellular proliferation and migration.Our findings suggest that the PP depot has the potential to modulate extra-prostatic tumor cells' microenvironment through increased MMPs activity and to promote prostate cancer cell survival and migration. Adipocyte-derived factors likely have a relevant proliferative and motile role.CONCLUSIONSOur findings suggest that the PP depot has the potential to modulate extra-prostatic tumor cells' microenvironment through increased MMPs activity and to promote prostate cancer cell survival and migration. Adipocyte-derived factors likely have a relevant proliferative and motile role.
Doc number: 32 Abstract Background: Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often infiltrated by malignant cells, to cancer progression is largely unknown. Thus, this study aimed to determine if periprostatic adipose tissue is linked with aggressive tumor biology in prostate cancer. Methods: Supernatants of whole adipose tissue (explants) or stromal vascular fraction (SVF) from paired fat samples of periprostatic (PP) and pre-peritoneal visceral (VIS) anatomic origin from different donors were prepared and analyzed for matrix metalloproteinases (MMPs) 2 and 9 activity. The effects of those conditioned media (CM) on growth and migration of hormone-refractory (PC-3) and hormone-sensitive (LNCaP) prostate cancer cells were measured. Results: We show here that PP adipose tissue of overweight men has higher MMP9 activity in comparison with normal subjects. The observed increased activities of both MMP2 and MMP9 in PP whole adipose tissue explants, likely reveal the contribution of adipocytes plus stromal-vascular fraction (SVF) as opposed to SVF alone. MMP2 activity was higher for PP when compared to VIS adipose tissue. When PC-3 cells were stimulated with CM from PP adipose tissue explants, increased proliferative and migratory capacities were observed, but not in the presence of SVF. Conversely, when LNCaP cells were stimulated with PP explants CM, we found enhanced motility despite the inhibition of proliferation, whereas CM derived from SVF increased both cell proliferation and motility. Explants culture and using adipose tissue of PP origin are most effective in promoting proliferation and migration of PC-3 cells, as respectively compared with SVF culture and using adipose tissue of VIS origin. In LNCaP cells, while explants CM cause increased migration compared to SVF, the use of PP adipose tissue to generate CM result in the increase of both cellular proliferation and migration. Conclusions: Our findings suggest that the PP depot has the potential to modulate extra-prostatic tumor cells' microenvironment through increased MMPs activity and to promote prostate cancer cell survival and migration. Adipocyte-derived factors likely have a relevant proliferative and motile role.
Abstract Background Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often infiltrated by malignant cells, to cancer progression is largely unknown. Thus, this study aimed to determine if periprostatic adipose tissue is linked with aggressive tumor biology in prostate cancer. Methods Supernatants of whole adipose tissue (explants) or stromal vascular fraction (SVF) from paired fat samples of periprostatic (PP) and pre-peritoneal visceral (VIS) anatomic origin from different donors were prepared and analyzed for matrix metalloproteinases (MMPs) 2 and 9 activity. The effects of those conditioned media (CM) on growth and migration of hormone-refractory (PC-3) and hormone-sensitive (LNCaP) prostate cancer cells were measured. Results We show here that PP adipose tissue of overweight men has higher MMP9 activity in comparison with normal subjects. The observed increased activities of both MMP2 and MMP9 in PP whole adipose tissue explants, likely reveal the contribution of adipocytes plus stromal-vascular fraction (SVF) as opposed to SVF alone. MMP2 activity was higher for PP when compared to VIS adipose tissue. When PC-3 cells were stimulated with CM from PP adipose tissue explants, increased proliferative and migratory capacities were observed, but not in the presence of SVF. Conversely, when LNCaP cells were stimulated with PP explants CM, we found enhanced motility despite the inhibition of proliferation, whereas CM derived from SVF increased both cell proliferation and motility. Explants culture and using adipose tissue of PP origin are most effective in promoting proliferation and migration of PC-3 cells, as respectively compared with SVF culture and using adipose tissue of VIS origin. In LNCaP cells, while explants CM cause increased migration compared to SVF, the use of PP adipose tissue to generate CM result in the increase of both cellular proliferation and migration. Conclusions Our findings suggest that the PP depot has the potential to modulate extra-prostatic tumor cells' microenvironment through increased MMPs activity and to promote prostate cancer cell survival and migration. Adipocyte-derived factors likely have a relevant proliferative and motile role.
ArticleNumber 32
Author Monteiro, Cátia
Cunha, Virgínia
Príncipe, Paulo
Mota-Pinto, Anabela
Lopes, Carlos
Fraga, Avelino
Sanches-Magalhães, José
Lobato, Carlos
Lobo, Francisco
Pina, Francisco
Ribeiro, Ricardo
Oliveira, Jorge
Oliveira, Maria José
Morais, António
Silva, Vítor
Freitas, Mariana
Medeiros, Rui
AuthorAffiliation 6 General Pathology Laboratory, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
13 Molecular Oncology Group - CI, Portuguese Institute of Oncology, Porto Centre, Edifício Laboratórios - Piso 4, Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal
12 Urology Department, S. João Hospital, Porto, Portugal
10 Urology Department, Porto Military Hospital, Porto, Portugal
7 CIMAGO, Centre of Investigation in Environment, Genetics and Oncobiology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
4 Biomaterials Division, NEWTherapies Group, INEB, Porto, Portugal
8 CNC, Centre of Neurosciences and Cell Biology, University of Coimbra, Coimbra, Portugal
11 Urology Department, Portuguese Institute of Oncology, Porto, Portugal
9 Urology Department, Porto Hospital Centre, Porto, Portugal
1 Molecular Oncology Group-CI, Portuguese Institute of Oncology, Porto, Portugal
3 Research Department-Portuguese League Against Cancer (NRNorte), LPCC, Porto, Portugal
2 Abel Salazar Biomedic
AuthorAffiliation_xml – name: 4 Biomaterials Division, NEWTherapies Group, INEB, Porto, Portugal
– name: 9 Urology Department, Porto Hospital Centre, Porto, Portugal
– name: 10 Urology Department, Porto Military Hospital, Porto, Portugal
– name: 13 Molecular Oncology Group - CI, Portuguese Institute of Oncology, Porto Centre, Edifício Laboratórios - Piso 4, Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal
– name: 2 Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal
– name: 6 General Pathology Laboratory, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
– name: 1 Molecular Oncology Group-CI, Portuguese Institute of Oncology, Porto, Portugal
– name: 11 Urology Department, Portuguese Institute of Oncology, Porto, Portugal
– name: 3 Research Department-Portuguese League Against Cancer (NRNorte), LPCC, Porto, Portugal
– name: 7 CIMAGO, Centre of Investigation in Environment, Genetics and Oncobiology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
– name: 8 CNC, Centre of Neurosciences and Cell Biology, University of Coimbra, Coimbra, Portugal
– name: 12 Urology Department, S. João Hospital, Porto, Portugal
– name: 5 Department of Pathology and Oncology, Faculty of Medicine, Porto, Portugal
Author_xml – sequence: 1
  givenname: Ricardo
  surname: Ribeiro
  fullname: Ribeiro, Ricardo
– sequence: 2
  givenname: Cátia
  surname: Monteiro
  fullname: Monteiro, Cátia
– sequence: 3
  givenname: Virgínia
  surname: Cunha
  fullname: Cunha, Virgínia
– sequence: 4
  givenname: Maria José
  surname: Oliveira
  fullname: Oliveira, Maria José
– sequence: 5
  givenname: Mariana
  surname: Freitas
  fullname: Freitas, Mariana
– sequence: 6
  givenname: Avelino
  surname: Fraga
  fullname: Fraga, Avelino
– sequence: 7
  givenname: Paulo
  surname: Príncipe
  fullname: Príncipe, Paulo
– sequence: 8
  givenname: Carlos
  surname: Lobato
  fullname: Lobato, Carlos
– sequence: 9
  givenname: Francisco
  surname: Lobo
  fullname: Lobo, Francisco
– sequence: 10
  givenname: António
  surname: Morais
  fullname: Morais, António
– sequence: 11
  givenname: Vítor
  surname: Silva
  fullname: Silva, Vítor
– sequence: 12
  givenname: José
  surname: Sanches-Magalhães
  fullname: Sanches-Magalhães, José
– sequence: 13
  givenname: Jorge
  surname: Oliveira
  fullname: Oliveira, Jorge
– sequence: 14
  givenname: Francisco
  surname: Pina
  fullname: Pina, Francisco
– sequence: 15
  givenname: Anabela
  surname: Mota-Pinto
  fullname: Mota-Pinto, Anabela
– sequence: 16
  givenname: Carlos
  surname: Lopes
  fullname: Lopes, Carlos
– sequence: 17
  givenname: Rui
  surname: Medeiros
  fullname: Medeiros, Rui
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22469146$$D View this record in MEDLINE/PubMed
BookMark eNp1kk1v1DAQhiNURD_gzA1F4sIlNOOv2BckqFpaqRIH4Gw5zmTxKrEXO1mJf4_TXVbdip7Gmnnn0TueOS9OfPBYFG-h_gggxSU0XFRKCVFRqCh5UZwdMieP3qfFeUrruhagQL0qTglhQgETZ8X323k0vtxgdJsY0mQmZ0vTuU1IWE4upRnLXBjDhKncK7C0xluMpVmtIqbktuhzKJ0vt26K4XXxsjdDwjf7eFH8vLn-cXVb3X_7enf1-b5qhSRTJQ3K2hLbNy3hfce5lILXDROmF9BQzq2VLVBam1Z12TDreEM4bTk2HbPS0IvibsftglnrTXSjiX90ME4_JEJcaRPzPAPqHhqpsOsF7RjrgbWUMUWskYz2kgnMrE871mZuR-ws-ima4Qh6XPHul16Fraa0UYrVGfBlB2hdeAZwXLFh1MuC9LIgTUFTkiEf9i5i-D1jmvToksVhMB7DnDTUBJQEIhfp-yfSdZijz__9oAJBQEJWvXs81sHOvwPIgsudwObdpoj9QQK1Xk7sPx75kw7rlrMJy1hueLbvL6551ZA
CitedBy_id crossref_primary_10_1016_j_bbalip_2013_02_010
crossref_primary_10_3390_cancers13215537
crossref_primary_10_1371_journal_pone_0123217
crossref_primary_10_3390_cancers14071679
crossref_primary_10_1038_s41598_021_97539_2
crossref_primary_10_1016_j_jnutbio_2014_11_001
crossref_primary_10_1186_s13148_018_0490_3
crossref_primary_10_1186_s13046_015_0178_x
crossref_primary_10_1007_s11690_014_0421_1
crossref_primary_10_1158_1541_7786_MCR_18_0748
crossref_primary_10_1111_andr_12331
crossref_primary_10_3390_cells12050802
crossref_primary_10_1007_s10495_017_1366_2
crossref_primary_10_4110_in_2018_18_e47
crossref_primary_10_1186_1741_7015_10_108
crossref_primary_10_1007_s10555_022_10056_0
crossref_primary_10_1186_1741_7015_10_109
crossref_primary_10_4103_tcmj_tcmj_62_22
crossref_primary_10_1186_s12894_017_0201_y
crossref_primary_10_1016_j_bcp_2024_116097
crossref_primary_10_1016_j_heliyon_2024_e30807
crossref_primary_10_1016_j_clgc_2013_07_013
crossref_primary_10_1002_stem_1857
crossref_primary_10_1016_j_clinbiochem_2012_12_012
crossref_primary_10_18632_oncotarget_11712
crossref_primary_10_1530_ERC_17_0466
crossref_primary_10_1186_1748_717X_9_93
crossref_primary_10_23902_trkjnat_978266
crossref_primary_10_1530_ERC_15_0556
crossref_primary_10_3892_ol_2024_14617
crossref_primary_10_1007_s40618_020_01294_6
crossref_primary_10_1590_1414_431x2024e13351
crossref_primary_10_4111_icu_20230215
crossref_primary_10_1155_2018_9247864
crossref_primary_10_1016_j_phrs_2018_02_022
crossref_primary_10_1002_jmri_24824
crossref_primary_10_1007_s10147_019_01559_y
crossref_primary_10_18632_oncotarget_10258
crossref_primary_10_12677_HJBM_2023_134046
crossref_primary_10_3390_ijms231810762
crossref_primary_10_1002_2211_5463_12976
crossref_primary_10_3390_ijms22094469
crossref_primary_10_1016_j_cytogfr_2017_11_002
crossref_primary_10_1515_hmbci_2015_0075
crossref_primary_10_3390_ijms24021229
crossref_primary_10_1002_pros_24117
crossref_primary_10_1038_s41585_023_00764_9
crossref_primary_10_1038_s41598_017_04951_8
crossref_primary_10_3389_fcell_2020_571648
crossref_primary_10_1016_j_canlet_2016_06_010
crossref_primary_10_1258_ebm_2012_012131
crossref_primary_10_1038_ncomms10230
crossref_primary_10_1002_pros_23158
crossref_primary_10_1186_s12885_024_13207_4
crossref_primary_10_1364_BOE_537783
crossref_primary_10_1289_ehp_1510090
crossref_primary_10_3389_fped_2014_00053
crossref_primary_10_3892_ol_2017_7454
crossref_primary_10_1007_s13277_013_1268_z
crossref_primary_10_1051_medsci_20163206012
crossref_primary_10_1007_s13277_016_5198_4
crossref_primary_10_1186_s12967_024_05458_3
crossref_primary_10_3390_cancers12092718
crossref_primary_10_1002_pros_22756
crossref_primary_10_3390_cancers14205077
crossref_primary_10_18632_aging_205065
crossref_primary_10_3390_cancers10120523
crossref_primary_10_1038_s41430_020_00713_4
crossref_primary_10_3390_jpm10040185
crossref_primary_10_18632_oncotarget_18038
crossref_primary_10_3390_biomedicines9111692
crossref_primary_10_1158_1055_9965_EPI_14_0236
crossref_primary_10_1016_j_urology_2016_07_042
crossref_primary_10_1016_j_actbio_2021_04_041
crossref_primary_10_3390_cancers12061385
crossref_primary_10_1111_bju_14173
crossref_primary_10_3390_nu7042539
crossref_primary_10_3390_cancers17030372
crossref_primary_10_1186_1756_9966_32_56
crossref_primary_10_1002_cam4_70001
crossref_primary_10_3390_cancers16152769
crossref_primary_10_3390_ijms242015140
crossref_primary_10_1016_j_isci_2022_104056
crossref_primary_10_1080_01635581_2019_1633363
crossref_primary_10_1016_j_phrs_2020_104741
crossref_primary_10_1371_journal_pone_0091069
crossref_primary_10_1016_j_lfs_2023_122225
crossref_primary_10_1186_s13046_015_0127_8
crossref_primary_10_3892_ol_2019_10555
crossref_primary_10_3390_metabo11110765
crossref_primary_10_2131_jts_40_21
crossref_primary_10_1186_1756_9966_33_31
crossref_primary_10_1080_13685538_2018_1519695
crossref_primary_10_4137_LPI_S10871
crossref_primary_10_3389_fphar_2021_626155
crossref_primary_10_1002_pros_24054
crossref_primary_10_1016_j_juro_2013_06_050
crossref_primary_10_1080_01635581_2020_1856889
crossref_primary_10_1002_cbf_3979
crossref_primary_10_1530_EC_19_0029
crossref_primary_10_1530_ERC_18_0058
crossref_primary_10_3389_fphar_2023_1145860
crossref_primary_10_1002_ijc_31775
crossref_primary_10_1038_s41598_024_71862_w
crossref_primary_10_18632_oncotarget_6643
crossref_primary_10_1016_j_jab_2014_09_004
crossref_primary_10_1007_s13277_013_1439_y
crossref_primary_10_1186_1756_9966_32_77
crossref_primary_10_2214_AJR_14_12689
crossref_primary_10_18632_oncotarget_11131
Cites_doi 10.1111/j.1467-789X.2011.00917.x
10.1111/j.1464-410X.2008.07534.x
10.1038/nrc3174
10.1002/(SICI)1097-0029(19981201)43:5<395::AID-JEMT6>3.0.CO;2-T
10.1038/sj.pcan.4500844
10.1038/sj.ijo.0803632
10.1016/j.bbrc.2006.03.044
10.1002/pros.21029
10.1158/0008-5472.CAN-05-1231
10.1038/pcan.2009.11
10.1007/978-1-59745-245-8_14
10.1001/jama.293.17.2095
10.1074/jbc.M301158200
10.1128/MCB.01275-09
10.1002/(SICI)1097-0045(19990215)38:3<199::AID-PROS4>3.0.CO;2-H
10.1002/pros.2990220307
10.1016/j.canlet.2003.09.016
10.1111/j.1464-410X.2010.09811.x
10.1371/journal.pone.0013612
10.1111/j.1464-410X.2011.10453.x
10.1016/j.yexmp.2005.08.004
10.1158/0008-5472.CAN-10-3323
10.1152/ajpendo.00127.2007
10.1111/j.1365-201X.2005.01468.x
10.1158/1055-9965.EPI-09-0372
10.1016/j.bbrc.2006.07.139
10.1007/s00424-009-0693-8
10.1083/jcb.105.5.2409
10.1210/er.2010-0030
10.1016/j.juro.2009.06.015
10.1038/nm.2492
10.1002/(SICI)1097-0142(19991101)86:9<1775::AID-CNCR20>3.0.CO;2-L
10.1080/019021490944232
10.1172/JCI31791
10.1006/bbrc.1996.0178
10.1152/ajpendo.90316.2008
10.1111/j.1349-7006.2011.01861.x
10.1161/01.CIR.0000121425.42966.F1
10.4161/org.5.2.8347
10.1016/0006-291X(90)91449-3
10.1210/jc.2009-2623
10.1161/01.ATV.19.10.2323
10.1371/journal.pone.0027851
10.1152/physiol.00009.2005
10.1007/BF00689790
10.1046/j.1464-410X.2003.04218.x
10.1016/j.cell.2011.09.024
10.1016/S0022-5347(05)67318-1
10.1128/JCM.00667-10
10.1074/jbc.M709401200
10.1074/jbc.M304984200
10.1007/s00394-009-0775-6
10.1016/j.eururo.2007.03.054
10.1159/000337604
10.1007/s11745-011-3630-5
10.1097/01.ju.0000141582.15218.10
10.1002/jcp.22455
10.1006/bbrc.1999.0515
10.1016/j.peptides.2009.10.001
10.1038/nrc745
10.1016/S0022-4804(03)00166-5
10.1046/j.1432-0436.2002.700905.x
ContentType Journal Article
Copyright 2012 Ribeiro et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright ©2012 Ribeiro et al; licensee BioMed Central Ltd. 2012 Ribeiro et al; licensee BioMed Central Ltd.
Copyright_xml – notice: 2012 Ribeiro et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
– notice: Copyright ©2012 Ribeiro et al; licensee BioMed Central Ltd. 2012 Ribeiro et al; licensee BioMed Central Ltd.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/1756-9966-31-32
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
ProQuest Health & Medical Collection (NC LIVE)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Publicly Available Content Database

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-9966
EndPage 32
ExternalDocumentID oai_doaj_org_article_f1789edf63d44f14b34492ca843f846e
PMC3379940
oai_biomedcentral_com_1756_9966_31_32
2691878671
22469146
10_1186_1756_9966_31_32
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
0R~
29K
2VQ
2WC
4.4
5GY
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ADBBV
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHSBF
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
D-I
DIK
DU5
E3Z
EBD
EBLON
EBS
EJD
ESX
F5P
FYUFA
GROUPED_DOAJ
H13
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
TR2
TUS
UKHRP
~8M
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
PUEGO
-5E
-5G
-A0
-BR
ABVAZ
ACRMQ
ADINQ
AFGXO
AFNRJ
C24
5PM
ID FETCH-LOGICAL-b682t-8ae80c2cf7b25fd5588650746af617355cc8b1330ab9d2464d57253b5e7d4c8a3
IEDL.DBID RBZ
ISSN 1756-9966
0392-9078
IngestDate Wed Aug 27 01:30:32 EDT 2025
Thu Aug 21 18:21:45 EDT 2025
Wed May 22 07:15:40 EDT 2024
Sun Aug 24 04:10:05 EDT 2025
Fri Jul 25 01:10:11 EDT 2025
Thu Apr 03 06:55:19 EDT 2025
Thu Apr 24 22:53:15 EDT 2025
Tue Jul 01 02:26:23 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License http://creativecommons.org/licenses/by/2.0
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b682t-8ae80c2cf7b25fd5588650746af617355cc8b1330ab9d2464d57253b5e7d4c8a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-News-3
content type line 23
OpenAccessLink http://dx.doi.org/10.1186/1756-9966-31-32
PMID 22469146
PQID 1021162181
PQPubID 105475
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_f1789edf63d44f14b34492ca843f846e
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3379940
biomedcentral_primary_oai_biomedcentral_com_1756_9966_31_32
proquest_miscellaneous_1021981282
proquest_journals_1021162181
pubmed_primary_22469146
crossref_primary_10_1186_1756_9966_31_32
crossref_citationtrail_10_1186_1756_9966_31_32
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2012-04-02
PublicationDateYYYYMMDD 2012-04-02
PublicationDate_xml – month: 04
  year: 2012
  text: 2012-04-02
  day: 02
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of experimental & clinical cancer research
PublicationTitleAlternate J Exp Clin Cancer Res
PublicationYear 2012
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References M Iwamura (569_CR34) 1993; 22
SY Sung (569_CR64) 2002; 70
J Chen (569_CR43) 2011; 12
T Mistry (569_CR29) 2007; 52
DP Chopra (569_CR36) 2004; 203
RC van Kruijsdijk (569_CR2) 2009; 18
D Desbois (569_CR17) 2010; 48
JM Wang (569_CR54) 1990; 169
J Park (569_CR1) 2011; 32
JG van Roermund (569_CR8) 2011; 107
L Cheng (569_CR5) 1999; 86
CY Lin (569_CR26) 2011; 102
TD Chung (569_CR32) 1999; 38
G Ferry (569_CR55) 2003; 278
S Chakrabarti (569_CR25) 2005; 31
M Zeyda (569_CR39) 2007; 31
JL Mohler (569_CR42) 1993; 12
PC Albertsen (569_CR18) 2005; 293
T Mistry (569_CR37) 2006; 348
CY Huang (569_CR47) 2011; 226
M Takahashi (569_CR50) 1996; 219
RJ Ribeiro (569_CR15) 2012; 29
SJ Freedland (569_CR4) 2009; 12
M Kinoshita (569_CR51) 1999; 19
Y Tokuda (569_CR13) 2003; 91
A Wells (569_CR44) 1998; 43
DS Finley (569_CR7) 2009; 182
A Mizokami (569_CR35) 2000; 164
S Kharait (569_CR41) 2006; 343
S Toda (569_CR63) 2009; 5
Y Wu (569_CR60) 2008; 295
J Azare (569_CR56) 2011; 6
EH Allott (569_CR27) 2011
MR Hoda (569_CR31) 2008; 102
B Dirat (569_CR11) 2011; 71
RS Taichman (569_CR19) 2007; 117
ST Patel (569_CR61) 2010; 31
B Desai (569_CR45) 2008; 283
R Unal (569_CR22) 2010; 95
DH Geho (569_CR57) 2005; 20
E Maury (569_CR40) 2007; 293
P Somasundar (569_CR14) 2003; 113
S Thalmann (569_CR16) 2008; 456
U Capitanio (569_CR3) 2011; 109
M Notarnicola (569_CR21) 2012; 47
V Subramaniam (569_CR46) 2005; 79
J Rehman (569_CR38) 2004; 109
KL Andarawewa (569_CR62) 2005; 65
G Taraboletti (569_CR53) 1987; 105
KM Nieman (569_CR9) 2011; 17
S Mori (569_CR33) 1999; 257
A O'Hara (569_CR59) 2009; 458
MV Hoang (569_CR52) 2010; 5
M Onuma (569_CR12) 2003; 278
CH Tang (569_CR48) 2009; 69
M Egeblad (569_CR23) 2002; 2
MJ Khandekar (569_CR58) 2011; 11
K Schnabele (569_CR10) 2009; 48
P Trayhurn (569_CR28) 2005; 184
S Valastyan (569_CR6) 2011; 147
LW Chung (569_CR20) 2005; 173
R Lichtinghagen (569_CR24) 2003; 23
E Im (569_CR49) 2010; 30
R Ribeiro (569_CR30) 2006; 9
15888576 - Physiology (Bethesda). 2005 Jun;20:194-200
12699491 - BJU Int. 2003 May;91(7):716-20
19819277 - Peptides. 2010 Jan;31(1):51-7
21049044 - PLoS One. 2010;5(10):e13612
3680388 - J Cell Biol. 1987 Nov;105(5):2409-15
17593905 - Int J Obes (Lond). 2007 Sep;31(9):1420-8
15592017 - J Urol. 2005 Jan;173(1):10-20
11990853 - Nat Rev Cancer. 2002 Mar;2(3):161-74
16322233 - Cancer Res. 2005 Dec 1;65(23):10862-71
21459803 - Cancer Res. 2011 Apr 1;71(7):2455-65
16344847 - Prostate Cancer Prostatic Dis. 2006;9(1):19-24
19169726 - Eur J Nutr. 2009 Apr;48(3):154-61
12894549 - Anticancer Res. 2003 May-Jun;23(3B):2617-24
21777363 - BJU Int. 2012 Mar;109(5):678-84
21219539 - Cancer Sci. 2011 Apr;102(4):815-27
16564022 - Biochem Biophys Res Commun. 2006 May 12;343(3):848-56
17786228 - J Clin Invest. 2007 Sep;117(9):2351-61
16019990 - Exp Lung Res. 2005 Jul-Aug;31(6):599-621
18492766 - Am J Physiol Endocrinol Metab. 2008 Jul;295(1):E205-15
20392866 - J Clin Endocrinol Metab. 2010 Jun;95(6):2993-3001
14993122 - Circulation. 2004 Mar 16;109(10):1292-8
22140473 - PLoS One. 2011;6(11):e27851
10198259 - Biochem Biophys Res Commun. 1999 Apr 13;257(2):609-14
15870412 - JAMA. 2005 May 4;293(17):2095-101
12492493 - Differentiation. 2002 Dec;70(9-10):506-21
8619824 - Biochem Biophys Res Commun. 1996 Feb 6;219(1):40-6
22090062 - Lipids. 2012 Jan;47(1):59-63
12902351 - J Biol Chem. 2003 Oct 24;278(43):42660-7
19755644 - Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2569-78
16026420 - Acta Physiol Scand. 2005 Aug;184(4):285-93
17578888 - Am J Physiol Endocrinol Metab. 2007 Sep;293(3):E656-65
21050356 - BJU Int. 2011 Jun;107(11):1775-9
19683746 - J Urol. 2009 Oct;182(4):1621-7
10068344 - Prostate. 1999 Feb 15;38(3):199-207
20231358 - Mol Cell Biol. 2010 May;30(10):2401-10
20945385 - J Cell Physiol. 2011 May;226(5):1274-82
22113164 - Nat Rev Cancer. 2011 Dec;11(12):886-95
12943810 - J Surg Res. 2003 Jul;113(1):50-5
10953159 - J Urol. 2000 Sep;164(3 Pt 1):800-5
10521360 - Arterioscler Thromb Vasc Biol. 1999 Oct;19(10):2323-9
19585142 - Pflugers Arch. 2009 Oct;458(6):1103-14
14732222 - Cancer Lett. 2004 Jan 20;203(2):145-54
17399889 - Eur Urol. 2007 Jul;52(1):46-53
22415092 - Cell Physiol Biochem. 2012;29(1-2):233-40
8488157 - Prostate. 1993;22(3):243-52
18337256 - J Biol Chem. 2008 May 16;283(20):13856-66
10547551 - Cancer. 1999 Nov 1;86(9):1775-82
19676095 - Prostate. 2009 Dec 1;69(16):1781-9
22000009 - Cell. 2011 Oct 14;147(2):275-92
18516562 - Methods Mol Biol. 2008;456:195-9
21642230 - Endocr Rev. 2011 Aug;32(4):550-70
18341625 - BJU Int. 2008 Aug;102(3):383-8
22093240 - Obes Rev. 2011 Dec;12(12):1063-70
22121096 - Mol Carcinog. 2013 Feb;52(2):144-54
9858337 - Microsc Res Tech. 1998 Dec 1;43(5):395-411
12642576 - J Biol Chem. 2003 May 16;278(20):18162-9
2190552 - Biochem Biophys Res Commun. 1990 May 31;169(1):165-70
19794899 - Organogenesis. 2009 Apr;5(2):50-6
16229833 - Exp Mol Pathol. 2005 Dec;79(3):187-93
20592136 - J Clin Microbiol. 2010 Sep;48(9):3306-15
8448827 - Cancer Metastasis Rev. 1993 Mar;12(1):53-67
19581922 - Prostate Cancer Prostatic Dis. 2009;12(3):259-63
22037646 - Nat Med. 2011;17(11):1498-503
16899222 - Biochem Biophys Res Commun. 2006 Sep 29;348(3):832-8
References_xml – volume: 12
  start-page: 1063
  year: 2011
  ident: 569_CR43
  publication-title: Obes Rev
  doi: 10.1111/j.1467-789X.2011.00917.x
– volume: 102
  start-page: 383
  year: 2008
  ident: 569_CR31
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2008.07534.x
– volume: 11
  start-page: 886
  year: 2011
  ident: 569_CR58
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3174
– volume: 43
  start-page: 395
  year: 1998
  ident: 569_CR44
  publication-title: Microsc Res Tech
  doi: 10.1002/(SICI)1097-0029(19981201)43:5<395::AID-JEMT6>3.0.CO;2-T
– volume: 9
  start-page: 19
  year: 2006
  ident: 569_CR30
  publication-title: Prostate Cancer Prostatic Dis
  doi: 10.1038/sj.pcan.4500844
– volume: 31
  start-page: 1420
  year: 2007
  ident: 569_CR39
  publication-title: Int J Obes (Lond)
  doi: 10.1038/sj.ijo.0803632
– volume: 343
  start-page: 848
  year: 2006
  ident: 569_CR41
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2006.03.044
– volume: 69
  start-page: 1781
  year: 2009
  ident: 569_CR48
  publication-title: Prostate
  doi: 10.1002/pros.21029
– volume: 65
  start-page: 10862
  year: 2005
  ident: 569_CR62
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-1231
– volume: 12
  start-page: 259
  year: 2009
  ident: 569_CR4
  publication-title: Prostate Cancer Prostatic Dis
  doi: 10.1038/pcan.2009.11
– volume: 456
  start-page: 195
  year: 2008
  ident: 569_CR16
  publication-title: Methods Mol Biol
  doi: 10.1007/978-1-59745-245-8_14
– volume: 293
  start-page: 2095
  year: 2005
  ident: 569_CR18
  publication-title: JAMA
  doi: 10.1001/jama.293.17.2095
– volume: 278
  start-page: 18162
  year: 2003
  ident: 569_CR55
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M301158200
– volume: 30
  start-page: 2401
  year: 2010
  ident: 569_CR49
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.01275-09
– volume: 38
  start-page: 199
  year: 1999
  ident: 569_CR32
  publication-title: Prostate
  doi: 10.1002/(SICI)1097-0045(19990215)38:3<199::AID-PROS4>3.0.CO;2-H
– volume: 22
  start-page: 243
  year: 1993
  ident: 569_CR34
  publication-title: Prostate
  doi: 10.1002/pros.2990220307
– volume: 203
  start-page: 145
  year: 2004
  ident: 569_CR36
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2003.09.016
– volume: 107
  start-page: 1775
  year: 2011
  ident: 569_CR8
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2010.09811.x
– volume: 5
  start-page: e13612
  year: 2010
  ident: 569_CR52
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0013612
– volume: 109
  start-page: 678
  year: 2011
  ident: 569_CR3
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2011.10453.x
– volume: 79
  start-page: 187
  year: 2005
  ident: 569_CR46
  publication-title: Exp Mol Pathol
  doi: 10.1016/j.yexmp.2005.08.004
– volume: 71
  start-page: 2455
  year: 2011
  ident: 569_CR11
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-3323
– volume: 293
  start-page: E656
  year: 2007
  ident: 569_CR40
  publication-title: Am J Physiol Endocrinol Metab
  doi: 10.1152/ajpendo.00127.2007
– volume: 184
  start-page: 285
  year: 2005
  ident: 569_CR28
  publication-title: Acta Physiol Scand
  doi: 10.1111/j.1365-201X.2005.01468.x
– volume: 18
  start-page: 2569
  year: 2009
  ident: 569_CR2
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-09-0372
– volume: 348
  start-page: 832
  year: 2006
  ident: 569_CR37
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2006.07.139
– volume-title: Mol Carcinog
  year: 2011
  ident: 569_CR27
– volume: 458
  start-page: 1103
  year: 2009
  ident: 569_CR59
  publication-title: Pflugers Arch
  doi: 10.1007/s00424-009-0693-8
– volume: 105
  start-page: 2409
  year: 1987
  ident: 569_CR53
  publication-title: J Cell Biol
  doi: 10.1083/jcb.105.5.2409
– volume: 32
  start-page: 550
  year: 2011
  ident: 569_CR1
  publication-title: Endocr Rev
  doi: 10.1210/er.2010-0030
– volume: 182
  start-page: 1621
  year: 2009
  ident: 569_CR7
  publication-title: J Urol
  doi: 10.1016/j.juro.2009.06.015
– volume: 17
  start-page: 1498
  year: 2011
  ident: 569_CR9
  publication-title: Nat Med
  doi: 10.1038/nm.2492
– volume: 86
  start-page: 1775
  year: 1999
  ident: 569_CR5
  publication-title: Cancer
  doi: 10.1002/(SICI)1097-0142(19991101)86:9<1775::AID-CNCR20>3.0.CO;2-L
– volume: 31
  start-page: 599
  year: 2005
  ident: 569_CR25
  publication-title: Exp Lung Res
  doi: 10.1080/019021490944232
– volume: 117
  start-page: 2351
  year: 2007
  ident: 569_CR19
  publication-title: J Clin Invest
  doi: 10.1172/JCI31791
– volume: 219
  start-page: 40
  year: 1996
  ident: 569_CR50
  publication-title: Biochem Biophys Res Commun
  doi: 10.1006/bbrc.1996.0178
– volume: 295
  start-page: E205
  year: 2008
  ident: 569_CR60
  publication-title: Am J Physiol Endocrinol Metab
  doi: 10.1152/ajpendo.90316.2008
– volume: 102
  start-page: 815
  year: 2011
  ident: 569_CR26
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2011.01861.x
– volume: 109
  start-page: 1292
  year: 2004
  ident: 569_CR38
  publication-title: Circulation
  doi: 10.1161/01.CIR.0000121425.42966.F1
– volume: 5
  start-page: 50
  year: 2009
  ident: 569_CR63
  publication-title: Organogenesis
  doi: 10.4161/org.5.2.8347
– volume: 169
  start-page: 165
  year: 1990
  ident: 569_CR54
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/0006-291X(90)91449-3
– volume: 95
  start-page: 2993
  year: 2010
  ident: 569_CR22
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2009-2623
– volume: 23
  start-page: 2617
  year: 2003
  ident: 569_CR24
  publication-title: Anticancer Res
– volume: 19
  start-page: 2323
  year: 1999
  ident: 569_CR51
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/01.ATV.19.10.2323
– volume: 6
  start-page: e27851
  year: 2011
  ident: 569_CR56
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0027851
– volume: 20
  start-page: 194
  year: 2005
  ident: 569_CR57
  publication-title: Physiology (Bethesda)
  doi: 10.1152/physiol.00009.2005
– volume: 12
  start-page: 53
  year: 1993
  ident: 569_CR42
  publication-title: Cancer Metastasis Rev
  doi: 10.1007/BF00689790
– volume: 91
  start-page: 716
  year: 2003
  ident: 569_CR13
  publication-title: BJU Int
  doi: 10.1046/j.1464-410X.2003.04218.x
– volume: 147
  start-page: 275
  year: 2011
  ident: 569_CR6
  publication-title: Cell
  doi: 10.1016/j.cell.2011.09.024
– volume: 164
  start-page: 800
  year: 2000
  ident: 569_CR35
  publication-title: J Urol
  doi: 10.1016/S0022-5347(05)67318-1
– volume: 48
  start-page: 3306
  year: 2010
  ident: 569_CR17
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.00667-10
– volume: 283
  start-page: 13856
  year: 2008
  ident: 569_CR45
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M709401200
– volume: 278
  start-page: 42660
  year: 2003
  ident: 569_CR12
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M304984200
– volume: 48
  start-page: 154
  year: 2009
  ident: 569_CR10
  publication-title: Eur J Nutr
  doi: 10.1007/s00394-009-0775-6
– volume: 52
  start-page: 46
  year: 2007
  ident: 569_CR29
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2007.03.054
– volume: 29
  start-page: 233
  year: 2012
  ident: 569_CR15
  publication-title: Cell Physiol Biochem
  doi: 10.1159/000337604
– volume: 47
  start-page: 59
  year: 2012
  ident: 569_CR21
  publication-title: Lipids
  doi: 10.1007/s11745-011-3630-5
– volume: 173
  start-page: 10
  year: 2005
  ident: 569_CR20
  publication-title: J Urol
  doi: 10.1097/01.ju.0000141582.15218.10
– volume: 226
  start-page: 1274
  year: 2011
  ident: 569_CR47
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.22455
– volume: 257
  start-page: 609
  year: 1999
  ident: 569_CR33
  publication-title: Biochem Biophys Res Commun
  doi: 10.1006/bbrc.1999.0515
– volume: 31
  start-page: 51
  year: 2010
  ident: 569_CR61
  publication-title: Peptides
  doi: 10.1016/j.peptides.2009.10.001
– volume: 2
  start-page: 161
  year: 2002
  ident: 569_CR23
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc745
– volume: 113
  start-page: 50
  year: 2003
  ident: 569_CR14
  publication-title: J Surg Res
  doi: 10.1016/S0022-4804(03)00166-5
– volume: 70
  start-page: 506
  year: 2002
  ident: 569_CR64
  publication-title: Differentiation
  doi: 10.1046/j.1432-0436.2002.700905.x
– reference: 17786228 - J Clin Invest. 2007 Sep;117(9):2351-61
– reference: 16344847 - Prostate Cancer Prostatic Dis. 2006;9(1):19-24
– reference: 20592136 - J Clin Microbiol. 2010 Sep;48(9):3306-15
– reference: 22140473 - PLoS One. 2011;6(11):e27851
– reference: 10953159 - J Urol. 2000 Sep;164(3 Pt 1):800-5
– reference: 19819277 - Peptides. 2010 Jan;31(1):51-7
– reference: 22037646 - Nat Med. 2011;17(11):1498-503
– reference: 10068344 - Prostate. 1999 Feb 15;38(3):199-207
– reference: 15592017 - J Urol. 2005 Jan;173(1):10-20
– reference: 20945385 - J Cell Physiol. 2011 May;226(5):1274-82
– reference: 22093240 - Obes Rev. 2011 Dec;12(12):1063-70
– reference: 18337256 - J Biol Chem. 2008 May 16;283(20):13856-66
– reference: 10198259 - Biochem Biophys Res Commun. 1999 Apr 13;257(2):609-14
– reference: 21642230 - Endocr Rev. 2011 Aug;32(4):550-70
– reference: 22090062 - Lipids. 2012 Jan;47(1):59-63
– reference: 12943810 - J Surg Res. 2003 Jul;113(1):50-5
– reference: 8619824 - Biochem Biophys Res Commun. 1996 Feb 6;219(1):40-6
– reference: 12642576 - J Biol Chem. 2003 May 16;278(20):18162-9
– reference: 12894549 - Anticancer Res. 2003 May-Jun;23(3B):2617-24
– reference: 8488157 - Prostate. 1993;22(3):243-52
– reference: 12492493 - Differentiation. 2002 Dec;70(9-10):506-21
– reference: 22415092 - Cell Physiol Biochem. 2012;29(1-2):233-40
– reference: 15888576 - Physiology (Bethesda). 2005 Jun;20:194-200
– reference: 18516562 - Methods Mol Biol. 2008;456:195-9
– reference: 21050356 - BJU Int. 2011 Jun;107(11):1775-9
– reference: 15870412 - JAMA. 2005 May 4;293(17):2095-101
– reference: 21777363 - BJU Int. 2012 Mar;109(5):678-84
– reference: 19169726 - Eur J Nutr. 2009 Apr;48(3):154-61
– reference: 19585142 - Pflugers Arch. 2009 Oct;458(6):1103-14
– reference: 14993122 - Circulation. 2004 Mar 16;109(10):1292-8
– reference: 11990853 - Nat Rev Cancer. 2002 Mar;2(3):161-74
– reference: 3680388 - J Cell Biol. 1987 Nov;105(5):2409-15
– reference: 18492766 - Am J Physiol Endocrinol Metab. 2008 Jul;295(1):E205-15
– reference: 17578888 - Am J Physiol Endocrinol Metab. 2007 Sep;293(3):E656-65
– reference: 14732222 - Cancer Lett. 2004 Jan 20;203(2):145-54
– reference: 18341625 - BJU Int. 2008 Aug;102(3):383-8
– reference: 8448827 - Cancer Metastasis Rev. 1993 Mar;12(1):53-67
– reference: 2190552 - Biochem Biophys Res Commun. 1990 May 31;169(1):165-70
– reference: 16019990 - Exp Lung Res. 2005 Jul-Aug;31(6):599-621
– reference: 10547551 - Cancer. 1999 Nov 1;86(9):1775-82
– reference: 10521360 - Arterioscler Thromb Vasc Biol. 1999 Oct;19(10):2323-9
– reference: 12699491 - BJU Int. 2003 May;91(7):716-20
– reference: 19755644 - Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2569-78
– reference: 21219539 - Cancer Sci. 2011 Apr;102(4):815-27
– reference: 21049044 - PLoS One. 2010;5(10):e13612
– reference: 19794899 - Organogenesis. 2009 Apr;5(2):50-6
– reference: 16564022 - Biochem Biophys Res Commun. 2006 May 12;343(3):848-56
– reference: 19581922 - Prostate Cancer Prostatic Dis. 2009;12(3):259-63
– reference: 19676095 - Prostate. 2009 Dec 1;69(16):1781-9
– reference: 21459803 - Cancer Res. 2011 Apr 1;71(7):2455-65
– reference: 20392866 - J Clin Endocrinol Metab. 2010 Jun;95(6):2993-3001
– reference: 17593905 - Int J Obes (Lond). 2007 Sep;31(9):1420-8
– reference: 22113164 - Nat Rev Cancer. 2011 Dec;11(12):886-95
– reference: 20231358 - Mol Cell Biol. 2010 May;30(10):2401-10
– reference: 22121096 - Mol Carcinog. 2013 Feb;52(2):144-54
– reference: 16322233 - Cancer Res. 2005 Dec 1;65(23):10862-71
– reference: 17399889 - Eur Urol. 2007 Jul;52(1):46-53
– reference: 9858337 - Microsc Res Tech. 1998 Dec 1;43(5):395-411
– reference: 12902351 - J Biol Chem. 2003 Oct 24;278(43):42660-7
– reference: 22000009 - Cell. 2011 Oct 14;147(2):275-92
– reference: 16899222 - Biochem Biophys Res Commun. 2006 Sep 29;348(3):832-8
– reference: 19683746 - J Urol. 2009 Oct;182(4):1621-7
– reference: 16026420 - Acta Physiol Scand. 2005 Aug;184(4):285-93
– reference: 16229833 - Exp Mol Pathol. 2005 Dec;79(3):187-93
SSID ssj0061919
Score 2.3355305
Snippet Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often infiltrated by...
Doc number: 32 Abstract Background: Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue,...
BACKGROUND: Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often...
Abstract Background Obesity is associated with prostate cancer aggressiveness and mortality. The contribution of periprostatic adipose tissue, which is often...
SourceID doaj
pubmedcentral
biomedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 32
SubjectTerms Adipose tissue
Adipose Tissue - enzymology
Adipose Tissue - pathology
Aged
Aggressiveness
Body fat
Cell line
Cell Proliferation
Cell tracking
Culture Media, Conditioned
Humans
In Vitro Techniques
Male
Matrix Metalloproteinase 2 - metabolism
Matrix Metalloproteinase 9 - metabolism
Medical research
Obesity
Obesity - pathology
Oncology
Periprostatic
Prostate cancer
Prostatic Neoplasms - enzymology
Prostatic Neoplasms - pathology
Rodents
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LbxMxELZQD4gLojzTlspIHLgsjd-2OEFFVSGVC1TqzfITIlWbKNny-xl7nSjLQ1y4-qH1jscz3_jxDUKvQ9nZZyF2LjoJAQoxnZ8H2mWRE41MRE3K4-Srz_Lymn-6ETd7qb7KnbCRHngU3FkmSpsUs2SR80y4Z5wbGpzmLIPvTMX6gs_bBlOjDYaooKb0AN8ou4LoG6kP0fJsVwbmp6tZR_Yfut9O_FOl8f8T9vz1CuWeT7p4hB42MInfjz9xiO6l_jG6f9WOy5-gL3WLHhcy41V53VHYWbGLi9Vyk_BQRY5X9T5e2uDWIuFQFGGN3bcaijdriBc9_rEY1sun6Pri49fzy65lUei81HTotEsapB-y8lTkKITWgMoUly4DegG4EYL2EKnOnTeRcsmjUFQwL5KKPGjHnqGDftmnFwgLaBGd8loSx_08m-QcB8vtwNESqugMvZvI0q5GxgxbOKynNbCcbJkJW2bCMmIZ9H67lbwNjaC85Mm4tTVQ0fL3Dm92HbZf-mvTD2UqJwOqBaBqtqma_ZeqzdDJVhFsW-kbW1KjE1mA0gy92lXDGi0HL65Py7uxjQEkpWEcz0e92Y2kEPoZcFczpCYaNRnqtKZffK884IwpY_j86H_82zF6AFCQ1jtJ9AQdDOu79BLg1uBP68r6CU5LKKU
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Health & Medical Collection (NC LIVE)
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4s1CQUbiwCV0Yzu2Iw4IEFWFVC5QaW-Wn2WlKgm7Kb-fGa83NLyusa2MPOOZb_z4hpCXHnf2uQ-VDVZCglK3lVt6VqUmRRZ4E3SNj5NPP8uTM_Fp1azKhtu2XKvc-8TsqEPvcY_8CEtQ1xID0tvhe4VVo_B0tZTQuE5uIHUZWrVaTQkX5Aa5sAdESFkhri_UPrWWR9M3cEJVrj1y9bn7xSxKZTL_vyHQ3y9SXolMx3fI7QIp6budDdwl12J3j9w8LYfm98mXvFFPkdJ4wDceyNFKbVgP_TbSMU88HfKtvLilpUekHs1hQ-15TsiLT6Trjv5Yj5v-ATk7_vj1w0lVailUTmo2VtpGDTrwSTnWpNA0WgM2U0LaBBgGQIf32kG-urSuDUxIERrFGu6aqILw2vKH5KDru_iY0AZ6BKuclrUVbpnaaK0A_20h3NZMsQV5M5tLM-x4MwwyWc9bQMEGNWFQE4bXhsPo1_uZN77QlGO1jAuT0xUt_xzwahqw_9M_u75HVc4Eyh_6zbkpK9WkWuk2hiR5ECLVwnEhWuatFjwBWIsLcrg3BFPW-9b8ss4FeTE1w0rF4xfbxf5y16cFPKVBjkc7u5kkQVq_FoLWgqiZRc1Enbd062-ZDZxz1bZi-eT_Yj0ltwDqsXzniB2Sg3FzGZ8BnBrd87xmfgIcOSAj
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF-kBfFFrJ9nq6zggy-pl_0OUoqKpQjnix70bdnPenAk11wq9r93di8XTT19zc4mw87Xb7K7Mwi9dunPPnW-MN4ISFDKqrBTR4rIYyCecq_KdDl59kWcz9nnC37xux1Qv4Drnald6ic1b5fHP69uTsHgT7LBK_EWIqAoEm4Hh1JQ8Mf7EJZkamcwY8OWAiQKucvHQNzX-dnxglt335ejkJUr---Co7dPVf4Rps4eoPs9vsTvNwpxgO6E-iG6O-t30B-hr_mvPU71jVfpwkcq2IqNX6yadcBdlgJe5SN6YY17ioBd0o0Wm8ucnfcOEi9q_GPRtc1jND_79O3jedE3ViisUKQrlAkKBOKitIRHz7lSANQkEyYCoAEE4pyykLxOja08YYJ5LgmnlgfpmVOGPkF7dVOHZwhzoPBGWiVKw-w0VsEYBs7cQOwtiSQT9G60lnq1KaKhU1nr8QhYmE6S0EkSmpaawuzj7cpr19csT60zljrnLkr8PeHNMGH7pX-SfkiiHDGUHzTtpe7NVsdSqir4KKhnLJbMUsYq4oxiNAJyCxN0tFUEvdVdnbqllyJhpwl6NQyD2aa9GFOH5npDUwG4UsDH043eDJykGn8VRLAJkiONGrE6HqkX33NpcEplVbHp8_-zdYjuAe4j-QASOUJ7XXsdXgC26uzLbDO_AEctIpQ
  priority: 102
  providerName: Scholars Portal
Title Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro
URI https://www.ncbi.nlm.nih.gov/pubmed/22469146
https://www.proquest.com/docview/1021162181
https://www.proquest.com/docview/1021981282
http://dx.doi.org/10.1186/1756-9966-31-32
https://pubmed.ncbi.nlm.nih.gov/PMC3379940
https://doaj.org/article/f1789edf63d44f14b34492ca843f846e
Volume 31
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxELaglRCXijcpJTISBy4LWb-tnhrUqkJKhYBKERfLzxKp2kTJtr-_Y2cT2FBOXHKIx4k145n5xo_PCL33eWWf-lDZYAUUKLWu3MiTKvEUSaA8qDpfTp5ciPNL9mXKp7_Jond28GslPkF-E1VG5RAuKgrRdp8wqOdyYT7-uQm6UAaUNzy2wh2Lzz0_sHOz_bqXkApv_31gc_fM5B9J6OwJOujQIz5Zm_spehCbZ-jRpNsff46-lzV5nNmLF_k6R6ZjxTbMFvNVxG3RMV6UA3hxhTuJiH22_BLbq1J7d-EPzxp8O2uX8xfo8uz0x-fzqns2oXJCkbZSNipQt0_SEZ4C50oBDJNM2ARwBfCF98pBaTqyTgfCBAtcEk4djzIwryx9ifaaeRNfI8xBIljplKgtc6Oko7UMQrWFzFoTSQbouKdLs1hTZJhMWt1vAf8x2RImW8LQ2lDo_XGjeeM7RvL8MMa1KZWJEn93-LDtsPmnf4qOsyl7AypfwNQynVOaVEulY0iCBsZSzRxlTBNvFaMJcFkcoKPNRDCda69Mfgu9FhkZDdC7bTM4Zd5psU2c36xlNEAnBeN4tZ4325FkBj8N-WmAZG9G9Ybab2lmvwrxN6VSazY6_C-tv0GPAfSRcvqIHKG9dnkT3wKwat0QPZRTOUT749OLr9-GZXkCPidMDYuz3QFsliVw
linkProvider BioMedCentral
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYAL4s1CASOBxCU0sR3HEUKIV7Wl3V5opb0Zx3bKSlUSdlMQf4rfyIyTLA2vW69-JCPPeL4Zjz1DyBOLJ_vcusg4I8FBSfKoiC2LyrT0zPHUqQQfJ88O5PRIfJin8w3yY3gLg9cqB50YFLWrLZ6Rb2MJ6kQiIL1qvkRYNQqjq0MJjU4s9vz3b-CyrV7uvgP-PmVs5_3h22nUVxWICqlYGynjFVBjy6xgaenSVCmwUjIhTQloDvBrrSrAc4tNkTsmpHBpxlJepD5zwirD4bsXyEUA3hidvWy-dvDAFwmFRACRZYR-RJ9KKFFye90GSi8KtU7OPq8_GaFiKB7wN4v394ubZ5Bw5xq52puw9HUnc9fJhq9ukEuzPkh_k3wMgQGKKZQbfFOCOWGpcYumXnnaBkbTJtwC9Cvaj_DUovgtqTkOBwC9DqaLin5dtMv6Fjk6l1W-TTaruvJ3CU1hhDNZoWRiRBGXuTdGAF4YgPeEZWxCXozWUjddng6NmbPHPSBQGjmhkROaJ5rD7OfDymvbp0XH6hwnOrhHSv454dl6wvCnfw59g6wcERQa6uWx7jWDLpNM5d6VkjshykQUXIicWaMEL8E49BOyNQiC7vXLSv_aDRPyeN0NmgHDPaby9Wk3Jgf7TQEddzq5WVOCaQRzAMkJyUYSNSJ13FMtPofs45xneS7ie_8n6xG5PD2c7ev93YO9--QKmJks3HdiW2SzXZ76B2DKtcXDsH8o-XTeG_Ynwc1cGg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaqIlVcEG8WChiJA5e0G7_iiBMFVuXRCgGVKi6W48d21VUS7ab8fsaOs9qUcuK2Wo93rZnx-JvE8w1Cr014sk-NzbTVAhKUvMyqqSGZ594RS7mVeShOPjkVx2fs8zk_30HzoRYmabDx2wT3Q5GgCYpYJRaci4PtAvVljOrwwVwettb3wUCKQzgdRRYwPQSbjEKsvlVwXoRWB9-Pfg0hG5KI2AFkI5w4gG74gWt18cvRcRZZ_2-CqtdvXG4dYbO76E7Cnvhd7yz30I6r76O9k_R2_QH6EZ_o46CRNhSDBDJXrO2ibdYOd9FCuI3X99waJwmHe3VhPY-ZewqeeFHj34tu1TxEZ7OPP98fZ6npQlYJSbpMaifBWMYXFeHeci4lgLiCCe0B7AA6MUZWkNhOdVVawgSzoE5OK-4Ky4zU9BHarZvaPUGYg4TVRSVFrlk19aXTmkGg13Au56QgE_R2pEvV9gQbKlBej0fAuCpYQgVLKJorCrMPBs0rk_jMQ1uNpYp5jRR_T3izmTD80z9Fj4IpRwuKXzSruUpbWvm8kKWzXlDLmM9ZRRkridGSUQ-ozk3Q_uAIKrn1WoVO6rkIuGqCXm2GYUuH9zS6ds1VL1MC8JKwjse932xWEvj_SjjdJqgYedRoqeORenERacMpLcqSTZ_-l9Zfor1vH2bq66fTL8_QbUCPJF5jIvtot1tdueeA0LrqRdxdfwDMKD0h
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Human+periprostatic+adipose+tissue+promotes+prostate+cancer+aggressiveness+in+vitro&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Ribeiro%2C+Ricardo&rft.au=Monteiro%2C+C%C3%A1tia&rft.au=Cunha%2C+Virg%C3%ADnia&rft.au=Oliveira%2C+Maria+Jos%C3%A9&rft.date=2012-04-02&rft.pub=BioMed+Central&rft.issn=1756-9966&rft.volume=31&rft_id=info:doi/10.1186%2F1756-9966-31-32&rft.externalDocID=2691878671
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon